Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
RESEARCH TOOLSreports
VRCA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.61 - $11.41
Previous CloseN/A
Volume115.12K
Average Volume (3M)564.36K
Market Cap
$65.46M
Enterprise Value$92.02M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Feb 27, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding90,564,840
10 Day Avg. Volume314,272
30 Day Avg. Volume564,364
Standard Deviation0.29
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.58
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.02
Enterprise Value/Ebitda-1.24
Forecast
1Y Price Target
$2.50Price Target Upside278.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Verrica Pharmaceuticals News
PremiumCompany Announcements
Verrica Pharmaceuticals Appoints New Chief Operating Officer
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe VP-315 showed compelling open-label proof of concept data including a 51% clearance rate and over 70% residual carcinoma tumor size reduction.
Operational EfficiencyVerrica is making continued progress on these fronts, reducing PAs, adding specialty and brown-bag availability, improving copay programs, and adding 'dual benefit' coverage.
Product DemandThere appears to be increasing demand in Q3, with 7,706 applicators dispensed, a 29% increase compared to Q2.
Bears Say
Corporate RestructuringVerrica's shakeup continues, with management departures and headcount reductions culminating with new CEO and interim CFO appointments.
Financial PerformanceVRCA reported negative net product revenues for 3Q24 and expects existing distributor inventory to remain high.
Product Launch ChallengesThe promising initial YCANTH launch quickly ran into headwinds regarding payer prior authorizations and compounded cantharidin.
---
Ownership Overview
45.74% Insiders
3.43% Mutual Funds
0.09% Other Institutional Investors
47.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $0.61 and its highest was $11.41 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $65.46M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Feb 27, 2025 which is in 15 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Nov 04, 2024. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.376 by -$0.114.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.25.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 90,564,840 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.376. Following the earnings report the stock price went down -44.056%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in VRCA
---
Verrica Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (278.79% Upside)
$2.50 (278.79% Upside)
Blogger Sentiment
Bullish
VRCA Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 15.0%
Last 30 Days ▼ 15.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.75%
12-Months-Change
Fundamentals
Return on Equity
-2059.89%
Trailing 12-Months
Asset Growth
-66.11%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
---
VRCA Stock 12 Month Forecast
Average Price Target
$2.50
▲(278.79% Upside)
Technical Analysis
Cutera
―
Fresh Tracks Therapeutics
―
VYNE Therapeutics
―
Evolus
―
Journey Medical Corp
―
Best Analysts Covering VRCA
1 Year
---